Is Regeneron Pharmaceuticals Inc halal to invest in?

As of July 2026, Regeneron Pharmaceuticals Inc REGN is classified as not halal according to Musaffa’s Shariah screening methodology. This classification is based on an assessment of the company’s business activities and financial ratios against Islamic investment guidelines.

Is Regeneron Pharmaceuticals Inc a Shariah-compliant stock?

A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Regeneron Pharmaceuticals Inc using these criteria to determine its compliance status.

Can Muslims buy shares of Regeneron Pharmaceuticals Inc?

Muslim investors may consider investing in Regeneron Pharmaceuticals Inc if it meets Shariah compliance standards. Investors typically review the company's business activities, debt levels, and non-permissible income before making a decision.

Why is Regeneron Pharmaceuticals Inc classified as NOT HALAL?

Musaffa determines the Shariah status of Regeneron Pharmaceuticals Inc by analyzing whether the company's core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.

How often is the Shariah compliance for Regeneron Pharmaceuticals Inc updated?

The Shariah compliance status of Regeneron Pharmaceuticals Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.

Can a halal stock like Regeneron Pharmaceuticals Inc become non-compliant?

Yes. A stock that is currently Shariah-compliant may become non-compliant if the company's financial ratios exceed Shariah thresholds or its business activities change.

Where can I check the Shariah status of Regeneron Pharmaceuticals Inc?

You can check the latest Shariah compliance status of Regeneron Pharmaceuticals Inc on Musaffa's stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.

REGN Shariah Compliance

Screening Methodology: AAOIFI

As of July 2026, Regeneron Pharmaceuticals Inc is classified as not halal.

NOT HALAL

Report Source: 2026 1st Quarter Report

Regeneron Pharmaceuticals Inc. Stock Analysis REGN

United States Health Care Large Cap Report: Q1, 2026

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. The company is headquartered in Tarrytown, New York and currently employs 15,410 full-time employees. The firm invents, develops, manufactures, and commercializes medicines for people with serious diseases. Its products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. The firm is accelerating drug development using its proprietary technologies, such as VelociSuite, which produces optimized fully human antibodies and new classes of bispecific antibodies. VelociSuite consists of VelocImmune, VelociGene, VelociMouse, VelociMab, Veloci-Bi, VelociT, VelociHum, and other related technologies. Its marketed products include EYLEA (aflibercept); Dupixent (dupilumab); Libtayo (cemiplimab); Ordspono (odronextamab); Kevzara (sarilumab); Itepekimab; Lynozyfic, and others.

Key Statistics of Regeneron Pharmaceuticals Inc (REGN)

Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.

Today's Range

$676.46$696.74

Today's Open

$676.93

Volume

900.41K

P/E Ratio (TTM)

15.58

52 Week Range

$541.00$821.11

Market Cap

69.50B

Avg. Volume

755.63K

Dividend Yield

0.53%

Financial Metrics & Statements of Regeneron Pharmaceuticals Inc (REGN)

Super Investors Invested in Regeneron Pharmaceuticals Inc (REGN)

FAQ's for Regeneron Pharmaceuticals Inc (REGN)

As of July 2026, Regeneron Pharmaceuticals Inc REGN is classified as not halal according to Musaffa’s Shariah screening methodology. This classification is based on an assessment of the company’s business activities and financial ratios against Islamic investment guidelines.
A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Regeneron Pharmaceuticals Inc using these criteria to determine its compliance status.
Muslim investors may consider investing in Regeneron Pharmaceuticals Inc if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
Musaffa determines the Shariah status of Regeneron Pharmaceuticals Inc by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
The Shariah compliance status of Regeneron Pharmaceuticals Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.
Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
You can check the latest Shariah compliance status of Regeneron Pharmaceuticals Inc on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.